Boston Scientific Corp. moved to acquire the balance of Nalu Medical Inc. in a $533 million cash deal, expanding its chronic ...

The U.S. FDA named the first nine recipients of the recently unveiled commissioner’s national priority voucher (CNPV) program ...

Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary ...

Two enzymes from the protein disulphide isomerase (PDI) family enable prostate cancer cells to grow, survive, and resist ...

Caught between the rock and the hard place of most-favored nation (MFN) pricing and the threat of a hefty biopharma sector ...

The full rights to Taysha Gene Therapies Inc.’s lead gene therapy candidate are coming back to the company. In 2022, Astellas ...

There was a curate’s egg for Sanofi SA from this month’s meeting of the EMA’s Committee for Medicinal Products for Human Use, ...

Med-tech M&A activity totaled $4.84 billion in September, down slightly from $7.29 billion in July but stronger than August’s ...

Biopharma companies announced $73.38 billion in deals from 240 transactions during the third quarter (Q3) of 2025, bringing ...

Total arterial revascularization (TAR) might not be the most popular approach to coronary artery bypass grafting (CABG), but it is gaining in popularity according to a new study appearing in the ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: A.D.A.M. Innovations, Alcon, Genesis, Samsung, Staar Surgical, Work Medical.

Xortx Therapeutics Inc. has entered into a binding term sheet to acquire a renal anti-fibrotic therapeutic program from ...